BIA Urges Biotechs To Flag Risks From UK R&D Tax Credit Reform
A UK government consultation on a new cap to R&D tax credits closes soon. The BIA is urging small companies to respond in an attempt to avert changes that could put small, virtual biotech firms out of business.
You may also be interested in...
A strong year is predicted for biopharma business with investment and deal making set to continue apace. Executives across industry share their forecasts for the year ahead.
Around 100 executives highlight the hot areas to watch on the R&D front in 2021. From cancer to CNS and from regenerative medicine to real world data, expectations are high on many fronts.
Executives share their expectations and hopes around the multi-faceted topic of patient access to medicines. From health inequities to value assessment and reimbursement trends, expectations for change abound.